Recent advancement in nanocarriers for oral vaccination
Source abstract
Abstract
Non-invasive mucosal immune response plays an important role in controlling various infections through mucosal route. Therefore, the appropriate induction of effective immune response should be elicited after immunization. Currently, a lot of strategies have been investigated to enhance the mucosal immunity including microparticles, liposomes, virosomes, cochleates and aracheosomes. These carriers due to tunable and unique physicochemical properties offer the possibility for better antigen presentation by appropriate cells, being more effective to induce a comparable immune response. The objective of this review is to give an overview of novel strategies for the delivery of vaccines through the mucosal route.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced Drug Delivery Systems · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics, I.S.F. College of Pharmacy
Department of Food Engineering,Inder Kumar Gujral Punjab Technical University
References (84)
Show source-provided references
1. 10.1038/nri325110.1038/nri3251 ↗
2. 10.1080/21691401.2017.134592710.1080/21691401.2017.1345927 ↗
3. 10.1016/j.addr.2011.07.00310.1016/j.addr.2011.07.003 ↗
4. 10.1637/10427-101812-Reg.110.1637/10427-101812-Reg.1 ↗
5. 10.1073/pnas.100645110710.1073/pnas.1006451107 ↗
6. 10.1016/j.addr.2011.05.01810.1016/j.addr.2011.05.018 ↗
7. 10.1016/j.it.2012.09.00610.1016/j.it.2012.09.006 ↗
8. 10.1038/nri277810.1038/nri2778 ↗
9. 10.1038/emm.2014.1610.1038/emm.2014.16 ↗
10. 10.1021/acs.molpharmaceut.5b0026510.1021/acs.molpharmaceut.5b00265 ↗
11. 10.1136/gut.13.1.4710.1136/gut.13.1.47 ↗
12. 10.1159/00023360210.1159/000233602 ↗
13. 10.1016/0264-410X(89)90156-410.1016/0264-410X(89)90156-4 ↗
14. 10.1007/978-3-642-74529-4_610.1007/978-3-642-74529-4_6 ↗
15. 10.1016/S0378-5173(02)00181-310.1016/S0378-5173(02)00181-3 ↗
16. 10.1016/0264-410X(93)90012-M10.1016/0264-410X(93)90012-M ↗
17. 10.1016/0264-410X(93)90018-S10.1016/0264-410X(93)90018-S ↗
18. 10.1046/j.1523-5378.1999.09046.x10.1046/j.1523-5378.1999.09046.x ↗
19. 10.1016/S0264-410X(94)80038-210.1016/S0264-410X(94)80038-2 ↗
20. 10.1016/S0264-410X(02)00613-810.1016/S0264-410X(02)00613-8 ↗
21. 10.1016/S0264-410X(01)00177-310.1016/S0264-410X(01)00177-3 ↗
22. 10.1016/S0168-3659(02)00276-610.1016/S0168-3659(02)00276-6 ↗
23. 10.1128/IAI.67.5.2643-2648.199910.1128/IAI.67.5.2643-2648.1999 ↗
24. 10.1128/IAI.70.3.1434-1442.200210.1128/IAI.70.3.1434-1442.2002 ↗
25. 10.1016/j.vaccine.2003.09.03410.1016/j.vaccine.2003.09.034 ↗
26. 10.1016/S0264-410X(02)00288-810.1016/S0264-410X(02)00288-8 ↗
27. 10.1046/j.1365-2567.1996.d01-639.x10.1046/j.1365-2567.1996.d01-639.x ↗
28. 10.1016/0168-3659(95)00155-710.1016/0168-3659(95)00155-7 ↗
29. 10.1016/S0264-410X(98)00437-X10.1016/S0264-410X(98)00437-X ↗
30. 10.1016/S0264-410X(00)00494-110.1016/S0264-410X(00)00494-1 ↗
31. 10.1128/IAI.67.7.3587-3592.199910.1128/IAI.67.7.3587-3592.1999 ↗
32. 10.1016/S0264-410X(00)00170-510.1016/S0264-410X(00)00170-5 ↗
33. 10.3109/21691401.2013.76944710.3109/21691401.2013.769447 ↗
34. 10.1016/S0165-2478(97)00131-410.1016/S0165-2478(97)00131-4 ↗
35. 10.1016/j.ijpharm.2015.04.04510.1016/j.ijpharm.2015.04.045 ↗
36. 10.1016/j.biomaterials.2013.10.02010.1016/j.biomaterials.2013.10.020 ↗
37. 10.1016/S0169-409X(97)00122-110.1016/S0169-409X(97)00122-1 ↗
38. 10.1016/S0142-9612(97)00227-510.1016/S0142-9612(97)00227-5 ↗
39. 10.1016/0378-5173(91)90246-K10.1016/0378-5173(91)90246-K ↗
40. 10.1006/viro.1999.975110.1006/viro.1999.9751 ↗
41. 10.1128/iai.64.2.489-494.199610.1128/iai.64.2.489-494.1996 ↗
42. 10.1128/iai.65.3.853-857.199710.1128/iai.65.3.853-857.1997 ↗
43. 10.3748/wjg.v8.i6.109810.3748/wjg.v8.i6.1098 ↗
44. 10.1080/0265204031000161979410.1080/02652040310001619794 ↗
45. 10.1016/j.vaccine.2017.08.01210.1016/j.vaccine.2017.08.012 ↗
46. 10.1016/j.vaccine.2003.12.01910.1016/j.vaccine.2003.12.019 ↗
47. 10.1016/S0168-3659(02)00280-810.1016/S0168-3659(02)00280-8 ↗
48. 10.1016/j.dci.2017.05.00410.1016/j.dci.2017.05.004 ↗
49. 10.1016/j.vetimm.2014.08.00610.1016/j.vetimm.2014.08.006 ↗
50. 10.1038/252252a010.1038/252252a0 ↗
51. 10.1016/j.colsurfb.2015.01.00510.1016/j.colsurfb.2015.01.005 ↗
52. 10.1016/j.jconrel.2016.12.00910.1016/j.jconrel.2016.12.009 ↗
53. 10.1517/13543776.18.11.127110.1517/13543776.18.11.1271 ↗
54. Thibodeau L Lavallee C inventors. Use of HIV-1 gp120 and gp160 proteins modified in the v3 loop for the preparation of vaccine compositions and formulations containing the same. Fondation Mondiale Recherche et Prevention Sida. Google Patent US7063849B1 (2006-06-20). 2006.
55. Okada J Cohen S Langer RS inventors. Oral delivery of vaccines using polymerized liposomes. Massachusetts Institute of Technology (Cambridge MA). US5762904 (1998-06-09). 1998.
56. Ford MJ inventor. Fusogenic liposomes that are free of active neuraminidase. Glaxo Wellcome Inc. US5985318A (1999-11-16). 1999.
57. 10.1021/acs.chemrev.5b0004610.1021/acs.chemrev.5b00046 ↗
58. 10.1016/j.vaccine.2015.03.08110.1016/j.vaccine.2015.03.081 ↗
59. 10.1016/j.ejpb.2014.04.00710.1016/j.ejpb.2014.04.007 ↗
60. 10.1155/2016/548208710.1155/2016/5482087 ↗
61. 10.1016/j.biomaterials.2016.01.05410.1016/j.biomaterials.2016.01.054 ↗
62. 10.1016/j.biomaterials.2009.10.00610.1016/j.biomaterials.2009.10.006 ↗
63. 10.1016/j.addr.2012.05.00910.1016/j.addr.2012.05.009 ↗
64. 10.2174/15672010577437028510.2174/156720105774370285 ↗
65. 10.1080/0738-85999122917010.1080/0738-859991229170 ↗
66. Sprott GD inventor. Formation of stable liposomes from lipid extracts of archaeobacteria (archaeu). National Research Council of Canada. US5989587A (1999-11-23). 1999.
67. Sprott GD inventor. Archaeosomes archaeosomes containing coenzyme Q10 and other types of liposomes containing coenzyme Q10 as adjuvants and as delivery vehicles. National Research Council of Canada. US6132789A (2000-10-17). 2000.
68. Unger EC inventor. Method for delivering bioactive agents using cochleates. ImaRx Therapeutics Inc. US6403056B1(2002-06-11). 2002.
69. Mannino RJ Fogerite SG inventors. Reconstituting viral glycoproteins into large phospholipid vesicles. Albany Medical College of Union University. US 4871488A(1989-10-03). 1989.
70. Margolis D Gould-Fogerite S Mannino RJ inventors. Integrative protein-DNA cochleate formulations and methods for transforming cells. University of Medicine and Dentistry of New Jersey University of Maryland Baltimore. US640591B1(2002-01-22). 2002.
71. 10.1016/j.ijpharm.2014.04.00210.1016/j.ijpharm.2014.04.002 ↗
72. Gould-Fogerite S Mannino RJ. Protein-or peptide-cochleate vaccines and methods of immunizing using the same. University of Medicine and Dentistry of New Jersey Albany Medical College. US5643574A(1997-07-01). 1997.
73. Schumacher R. Adjuvance of influenza virosomes in CTL induction in vitro PhD Thesis. Basel: University of Basel Faculty of Science; 2005.
74. Sharma R, Yasir M. Virosomes: a novel carrier for drug delivery. Int J Pharm Tech Res. 2010;2:2327–2339.
75. 10.1038/sj.gt.330049010.1038/sj.gt.3300490 ↗
76. Gluck R Mischler R. Hepatitis A virus in a reconstituted influenza virosome and use as a vaccine. Janssen Vaccines AG. US5565203A(1996-10-15). 1996.
77. 10.1128/IAI.68.10.5509-5516.200010.1128/IAI.68.10.5509-5516.2000 ↗
78. 10.1177/205101361454144010.1177/2051013614541440 ↗
79. 10.1292/jvms.16-033810.1292/jvms.16-0338 ↗
80. 10.1021/acs.molpharmaceut.6b0027410.1021/acs.molpharmaceut.6b00274 ↗
81. 10.2217/nnm.16.3610.2217/nnm.16.36 ↗
82. 10.1128/IAI.68.7.3830-3839.200010.1128/IAI.68.7.3830-3839.2000 ↗
83. 10.1128/IAI.01322-0810.1128/IAI.01322-08 ↗
84. 10.1139/cjm-2015-006310.1139/cjm-2015-0063 ↗